CClinicalTrials.gg
TerminatedNCT04059458FURC-III-REGENUpdated Nov 30, 2023

Mandibular Furcation III Regeneration (FURC-III-REGEN)

A Phase 4 interventional study of Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) and Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) in Furcation Defects and Periodontal Diseases, sponsored by University of Oslo. Terminated at 1 site in Norway. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by University of Oslo · Phase 4, Interventional, and Treatment

Why this study was terminated
Recruitment problem
Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Teeth with furcation grade III defects will be treated with open flap debridement and regenerative therapy with biphasic calcium phosphate combined with either enamel matrix proteins or a collagen membrane.

02

Conditions studied

  • Furcation Defects
  • Periodontal Diseases
03

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subject must be ≥ 20 years
  • Subject must have periodontal disease as determined by the World Workshop 2017 criteria
  • Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD >4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level
  • Competent to give consent

Exclusion criteria

Exclusion Criteria:

The following must not be present at the time of enrolment;

  • Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment
  • Present or past use of bisphosphonate treatment
  • Pregnant or nursing subjects
  • Patients classified as > class 2 according to the ASA (American Society of Anesthesiologists) physical status classification
  • Previous surgical therapy of included furcation defects
  • Inability to comprehend and respond to the quality of life questionnaire
  • Dental restorations or prosthesis involving the furcation area
  • Root fractures or suspected infractions
  • Caries lesions in the furcation area
  • No systemic antibiotic treatment within 3 months prior to intervention
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Regenerative therapy w/BCP and collagen membrane

    In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.

    Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) · Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)

  • Active comparator
    Regenerative therapy w/BCP and enamel matrix proteins

    In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.

    Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) · Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)

Interventions

  • DeviceBiphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)

    Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.

  • DrugBiphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)

    Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.

05

What researchers measure

Primary outcomes

  1. Change of furcation grade level

    Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe

    Time frame: 12 months after treatment

  2. Change of furcation grade level

    Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe

    Time frame: 24 months after treatment

Secondary outcomes

  1. Changes in patient-reported quality of life (QoL)

    To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome. Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1).

    Time frame: Preoperatively compared to 24 months after treatment

  2. Changes in patient-reported quality of life (QoL)

    To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome. Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1).

    Time frame: Preoperatively compared to 12 months after treatment

  3. Changes in defect morphology assessed by CBCT

    Cone beam computed tomography will be acquired at baseline, 2 weeks postoperatively and 24 months postoperatively. This outcome measures quantitative morphologic changes in the furcation defects at 24 months

    Time frame: 24 months after treatment

  4. Changes in pocket probing depth

    Changes in pocket probing depth will be measured with a probe

    Time frame: 12 months after treatment

  5. Changes in pocket probing depth

    Changes in pocket probing depth will be measured with a probe

    Time frame: 24 months after treatment

  6. Changes in PPD

    Changes in pocket probing depth will be measured with a probe

    Time frame: 12 months after treatment

  7. Changes in PPD

    Changes in pocket probing depth will be measured with a probe

    Time frame: 24 months after treatment

  8. Radiographic changes

    Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs

    Time frame: 12 months after treatment

  9. Radiographic changes

    Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs

    Time frame: 24 months after treatment

  10. Pain following surgery

    Pain sensation one week posteoperatively will be recorded on a visual analog scale from 0-10. 0 means no pain sensation, whereas 10 means highest pain imagineable.

    Time frame: Up to 1 week postoperatively

  11. Caries assessment

    Caries in furcation defect assessed with an explorer will be recorded as (Y/N)

    Time frame: 24 months

  12. Caries assessment

    Caries in furcation defect assessed with an explorer will be recorded as (Y/N)

    Time frame: 12 months

06

Study locations

1 site
  • Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo
    Oslo, 0455, Norway
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04059458
Lead sponsor
University of Oslo
Responsible party
Anders Verket (Associate Professor, University of Oslo) — Principal investigator
First posted
Aug 16, 2019
Start date
Oct 15, 2019
Primary completion
Nov 27, 2023
Completion
Nov 27, 2023
Last update
Nov 30, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion